查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1133475

红色生物技术全球市场-2022-2029

Global Red Biotechnology Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 250 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

红色生物技术市场的增长受到慢性病患病率上升、老年人口增加、靶向治疗的研发活动、医疗保健系统的快速扩张以及生物製剂技术进步的推动。

增加对慢性病和罕见病的补贴有望推动市场增长

癌症和心血管疾病等各种疾病的患病率上升预计将在预测期内提振市场。根据《2021 年罕见病数据报告》，世界卫生组织 (WHO) 报告称，罕见病是一种终生疾病或紊乱，其发生频率为千分之一或更少。在美国，罕见病被定义为影响该国少于 200,000 人（每 10,000 人中有 6.4 人）的疾病或病症。在欧盟，罕见病被定义为危及生命或长期使人衰弱的疾病，其影响不到 10,000 人中的 5 人。在日本，罕见病被定义为在日本影响不到 50,000 人（0.04%）的疾病。

此外，NICE（美国国家健康与护理卓越研究所）将在 2021 年发布最终指南，每个机构都在努力资助罕见病。新加坡为治疗三种罕见病的五种药物启动了罕见病基金，而马来西亚和澳大利亚则为符合条件的患者提供了高成本救命药物的补贴。此外，就慢性病而言，据 CDC 称，美国每年 3.8 万亿美元的医疗保健费用中有 90% 可以分配给患有慢性病和精神疾病的人。 《慢性病对策》出版物最近的一项合作研究发现，到 2030 年，治疗七种主要慢性病，再加上生产力损失，每年将使美国经济损失 2 万亿美元，即每人 8,600 美元。已决定增加对罕见病和慢性病的补贴将推动全球红色生物市场。

对罕见病认识不足阻碍市场增长

但是，对于罕见病，早期诊断是一项重大挑战，原因有很多，包括初级保健从业人员缺乏认识以及缺乏筛查和诊断设施。此外，患者数量有限，难以开发新药。这是红色生物技术市场的限制因素。

COVID-19 影响分析

COVID-19 的出现对全球红色生物技术市场产生了重大影响。在 COVID-19 大流行期间，生物技术公司需要大力支持传染病研究。许多 COVID-19 候选疫苗和 800 多项各种治疗方法和疫苗的临床试验都是由在传染病领域没有经验的公司开发的。显然，这些产品和公司中没有多少会在开发、资金或监管方面取得成功。 BIO 首席执行官 McMurry-Heath 也指出，由于 COVID-19 疾病的复杂性，多种药物机制都可以发挥作用。这种新的关注点开始以新疗法和候选疫苗的形式结出硕果。同时，COVID-19 大流行为世界各地的生物技术人员提供了独特的机会。世界正在寻求生物技术部门开发有效的解决方案，以帮助人类对抗和控制这场危机。此外，包括研究机构、政府机构和製药公司在内的生物技术行业正在共同努力开发检测工具、药物和疫苗，以应对这场衝突。因此，生物技术已成为抗击 COVID-19 的重要参与者。包括 Zydus Cadila、Serum Institute、Biological E、Bharat Biotech、Indian Immunologicals 和 Mynvax 在内的六家印度公司正在努力开发 COVID-19 疫苗，以快速应对这种在世界范围内迅速传播的致命疾病。全球努力开发预防方法。

全球红色生物技术市场报告将提供对大约 60 多个市场数据表、55 多个数字和 250 页（大约）的访问。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按产品类型划分的市场细分
  • 按应用划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因子
    • 驱动程序
      • 慢性病发病率不断上升
      • 研究活动增加
    • 约束因素
    • 技术和机械成本高
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 血液製品
  • 转基因药物
  • 人体疫苗
  • 诊断试剂
  • 个性化医疗
  • 其他

第 8 章. 按应用程序

  • 药物基因组学
  • 生物製药製造
  • 基因检测
  • 基因治疗

第 9 章，最终用户

  • 研究所
  • CMO·CRO
  • 生物製药公司
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 按地区分列的关键指标
      • 巴西
      • 阿根廷
      • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按治疗类型划分的基准

第 12 章公司简介

  • Hoffmann-La Roche, Ltd.
    • 公司概况
    • 治疗类型组合和描述
    • 主要亮点
    • 财务摘要
  • Merck KGaA
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Biogen Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Takeda Pharmaceutical Company Ltd.
  • Gilead Sciences, Inc.
  • Celgene Corporation

第 13 章全球红色生物技术市场-DataM

简介目录
Product Code: DMMD5856

Market Overview

Red Biotechnology Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.2% during the forecast period (2022-2029).

Red biotechnology indicates biopharmaceuticals. It involves the use of biotechnology in the medical field. It covers applications of biotechnology relating to clinical trials, vaccine development, disease research, antibiotic production, drug development, and molecular diagnostics.

Market Dynamics

The red biotechnology market growth is driven by the rise in prevalence of chronic disease, increase in the geriatric population, research and development activities for targeted therapies, rapid expansion in the healthcare system and technological advancements in biologics.

The rising funding for chronic and rare diseases is expected to drive the market growth

The rising prevalence of different diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. As per the 2021 rare disease data report, the World Health Organization (WHO) reports that a rare disease is a lifelong disease or disorder with a frequency of 1 or less per 1000 populations. In the United States, rare diseases are considered diseases or conditions that affect fewer than 200,000 patients in the country (6.4 in 10,000 people). The EU identifies rare diseases as life-threatening or chronically exhausting conditions affecting no more than 5 in 10,000 people. Japan defines rare diseases as diseases with fewer than 50,000 prevalent cases (0.04%) in the country.

In addition, the various authorities take initiatives for funding for rare diseases, such as in 2021, the National Institute for Health and Care Excellence (NICE) publication of final guidance. In Singapore, a rare disease fund was created to fund five medicines to treat three rare disease conditions, and in Malaysia and Australia, subsidised access for eligible patients is offered for high-cost and lifesaving drugs. Moreover, in the case of chronic diseases, according to the CDC, 90% of the nation's $3.8 trillion per year healthcare costs can be allotted to people with chronic diseases and mental health conditions. A recent collaboration to fight chronic disease publication decided that treatment of the seven major common chronic diseases, coupled with productivity losses, will cost the U.S. economy 2 trillion dollars annually, or USD 8,600 per person by 2030. Increasing the funding for rare and chronic diseases will boost the red biotechnology market worldwide.

The lack of awarenees of rare diseases will hamper the growth of the market

However, in the case of rare diseases, early diagnosis is the main challenge due to many factors, such as lack of awareness in primary care health care professional and lack of facilities for screening and diagnosis. In addition, it is difficult to develop a new drug due to a limited patient pool and the challenge becomes more greater when rare diseases are chronic in nature, where long-term stability is required. This factor limiting the red biotechnology market groeth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global red biotechnology market. During the COVID-19 pandemic, there was a massive pivot by biotechnology companies to follow infectious disease research. Many of the COVID-19 vaccine candidates and over 800 clinical trials for various treatments and vaccines were under development by companies without prior experience in the infectious disease area. Clearly, not many of these products and companies will receive development, funding, or regulatory success. In addition, McMurry-Heath (CEO of BIO) mentioned that the complexity of COVID-19 disease has allowed a role for multiple types of drug mechanisms to be effective. They have only started to see the results of this new focus in terms of new therapeutics and vaccine candidates. On the other hand, the COVID-19 pandemic provides a unique opportunity to biotechnologists across the globe. The world is looking toward the biotech sector to develop effective solutions that will help human beings fight and control the crisis. Furthermore, research organizations, government agencies, and biotech industries, including pharmaceutical companies, have collaborated to fight this conflict by developing detection tools, medicines, and vaccines. Biotechnology has thus turned up as a superior in the fight against COVID-19. Six Indian companies, including Zydus Cadila, Serum Institute, Biological E, Bharat Biotech, Indian Immunologicals, and Mynvax, were working on a vaccine for COVID-19, contributing to global efforts to develop a quick preventive for the deadly infection spreading rapidly across the world.

Segment Analysis

The biopharmaceutical industries segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The biopharmaceutical industry segment is expected to boost the market over the period of the forecast. This is owing to the increased approval of different therapies for diseases such as cancer. Biopharmaceuticals are pharmaceuticals drugs that are developed by using biotechnology. Biopharmaceuticals include DNA, RNA, proteins, antibodies, or antisense oligonucleotides used for therapeutic or diagnostic purposes. A growing number of new therapies for cancer and other diseases are being introduced as a result of advanced technology and the development of novel drugs. For instance, in 2020, Tecartus was approved for mantel cell lymphoma and acute lymphocytic leukemia in the US, UK, and EU by Gilead, and in 2021, Abecma was approved for multiple myeloma in the US, Canada, EU, UK, and Japan by Bluebird Bio. Due to the approval of new therapies for cancer, it is easily available for treatment in the region, which boosts the market. Furthermore, the rising incidence and prevalence of chronic and other diseases and the rapid advancement of the biopharmaceutical industry are the key driving factors in the biopharmaceutical industry segment.

Geographical Analysis

North America region holds the largest market share of the global Red Biotechnology market

North America dominates the market for red biotechnology and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure, healthcare spending, awareness among patients, and the availability of proper treatment for rare and chronic diseases. The approval of different gene therapies drives the market in the North American region. For instance, in 2020, a retroviral vector ex vivo was approved by the FDA for mantle cell lymphoma, and in 2021, the same vector was approved for certain types of large B-cell lymphoma. In addition, to date, the FDA has received more than 900 applications for scrutinscrutinine therapy in clinical trials. Furthermore, as per the American Society of Gene & Cell Therapy (ASGCT) 2021 report, one novel genetically modified cell therapy has been approved in 2022. Carvykti, a CAR-T cell therapy developed by Legend Biotech and Johnson & Johnson, was approved for multiple myeloma in the U.S. and EtranaDez (etranacogene dezaparvovec), an AAV5 gene therapy developed by uniQure, filed for approval in the EU and UK for hemophilia B. The launch of the new product in the United States boosts the red biotechnology market in the North American region.

Competitive Landscape

The red biotechnology market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Hoffmann-La Roche, Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Biogen Inc., Amgen Inc., AstraZeneca Plc., Takeda Pharmaceutical Company Ltd., Gilead Sciences, Inc., and Celgene Corporation among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the red biotechnology market globally.

For instance,

  • In August 2022, the U.S. FDA approved MYFEMBREE, developed by Myovant Sciences and Pfizer for the treatment of the management of moderate to severe pain associated with endometriosis. MYFEMBREE offers an efficient once-daily therapy option for the control of moderate to severe endometriosis-related pain.
  • In June 2022, Amgen's RIABNI (RITUXIMAB-ARRX), a biosimilar to RITUXAN (RITUXIMAB), received FDA approval for adults with moderate to severe rheumatoid arthritis.

Biogen Inc.

Overview:

Biogen finds, develops, and distributes worldwide innovative therapies for people living with neurological and neurodegenerative diseases as well as related therapeutic areas. The company was founded in 1978 and has the leading portfolio of medicines to treat multiple sclerosis (MS), Alzheimer's disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. It also commercializes biosimilars of advanced biologics.

Treatment type Portfolio:

BENEPALI: It was approved by the European Commission (EC) in January 2016 for the treatment of adults with moderate to severe rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and plaque psoriasis. It is currently available in more than 20 countries in the Europe region and is the most recommended etanercept in the five largest European countries (Germany, UK, France, Italy, and Spain).

The global red biotechnology market report would provide access to approximately 60+ market data tables, 55+ figures, and in the range of 250 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Product Type
  • 3.2. Market snippet By Application
  • 3.3. Market snippet By End User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidences of chronic diseases
      • 4.1.1.2. The increasing number of research activities
    • 4.1.2. Restraints:
    • 4.1.3. High cost of technology and machinery
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Blood Products*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Gene Recombinant Drugs
  • 7.4. Human Vaccines
  • 7.5. Diagnostics Reagents
  • 7.6. Personalized Medicines
  • 7.7. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Pharmacogenomics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biopharmaceutical Production
  • 8.4. Genetic Testing
  • 8.5. Gene Therapy

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Research Institutes*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. CMOs & CROs
  • 9.4. Biopharmaceutical Industries
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. DRest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific ynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Hoffmann-La Roche, Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck KGaA
  • 12.3. Regeneron Pharmaceuticals, Inc.
  • 12.4. Pfizer, Inc.
  • 12.5. Biogen Inc.
  • 12.6. Amgen Inc.
  • 12.7. AstraZeneca Plc.
  • 12.8. Takeda Pharmaceutical Company Ltd.
  • 12.9. Gilead Sciences, Inc.
  • 12.10. Celgene Corporation

LIST NOT EXHAUSTIVE

13. Global Red Biotechnology Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us